Epic Sciences’ Post

When a tissue biopsy is not feasible for patients with metastatic breast cancer, DefineMBC can provide ER & HER2 status in addition to genomic alterations. Discover more at definembc.com. #definembc #liquidbiopsy #CTC #HER2 #ERexpression #metastaticbreastcancer #breastcancer #HER2low #ctDNA #discovermore #genomicalterations #proteinexpression #cellanalysis #bloodbiopsy #epicsciences #ESR1 

I know from clinical experience with liquid biopsy in the population of patients with stage IV colorectal cancer that a negative ctDNA blood test result can signify remission but does not = cure, unfortunately. A negative can turn positive later. The tests simply are not sensitive enough to detect the ctDNA in the blood from a small number of cancerous cells that may be dormant or not large enough to be imaged or detected by the ctDNA tests. It remains to be seen whether the early clue about ctDNA recurrence will translate into better patient outcomes with earlier active treatments. Liquid biopsy for cancer recurrence creates a new kind of patient-in-waiting https://lnkd.in/eadeCcE2

𝙀𝙭𝙘𝙞𝙩𝙞𝙣𝙜 𝙖𝙙𝙫𝙖𝙣𝙘𝙚𝙢𝙚𝙣𝙩𝙨 𝙞𝙣 𝙤𝙣𝙘𝙤𝙡𝙤𝙜𝙮!  Liquid biopsy technology is revolutionising cancer diagnostics and treatment. This non-invasive blood test detects tumour DNA, offering faster, safer, and more cost-effective insights compared to traditional biopsies. It's particularly beneficial for monitoring treatment effectiveness and personalising care for metastatic cancers. Some key players are listed below; 🧬 CellMax Life 🧬 AccuraGen 🧬 GRAIL 🧬 OncoDNA 🧬 Nucleix Ltd. #oncology #cancerdetection #industryinsights #diagnostics

Stage IB1 #cervicalcancer (.ie., >5 mm depth of stromal invasion and ≤2 cm in greatest dimension) is usually treated with radical #hysterectomy. However, in a randomized trial in 640 patients with IB1 cervical cancer, radical vs. simple hysterectomy with lymph node assessment resulted in similar 3-year recurrence rates (2.2 and 2.5 percent, respectively). Although data are limited, simple hysterectomy with lymph node assessment may be an acceptable alternative to radical hysterectomy for IB1 cervical cancer. Find out What's New in #gynecology: https://ow.ly/8OlI50RlHVe #ClinicalUpdates #meded

#publishedineinstein This study set out to evaluate the effect of intrathecal #chemotherapy on the overall survival and clinical benefits in patients with metastatic breast cancer and meningeal carcinomatosis.   Full article at https://lnkd.in/dg4DXz8p   #visualabstract #journaleinstein #breastneoplasm #meningealcarcinomatosis #intrathecalchemotherapy #neurologicmanifestations

Using a patients live cancer cells to determine chemo therapy impact is crucial, especially when the standard of care drug has a low effectiveness. 1. Will TMZ kill my own cancer cells? 2. No, then what other chemo options are available that did kill my cancer cells and may get past the blood brain barrier? 3. None, then are their potential clinical trials I can enter? Diagnostics = information and more of that is always better - choose 3D Predict to learn what you don't know today and take action. #cancer #cancersucks #3DPredict #itsmycancer

This Brain Cancer Awareness Month, let's talk about change. At Kiyatec, change isn't just a vision—it's a calling. Our 3D Predict™ platform can predict which treatments for high-grade glioma will most likely work. Together, we're creating a reality where each patient's treatment is as unique as their fight. #BrainCancerAwarenessMonth #Kiyatec #3DPredict #DefeatGlioma #CancerTreatment #Oncology #Innovation #PatientCare #CancerAwareness #MedicalResearch #Chemotherapy

Early Detection is Key

1 in 8 men will be diagnosed with prostate cancer in their lifetime, but not all prostate cancer is aggressive or deadly, and early diagnosis is key. Select mdx fills the gap left by vague and inconsistent screening guidelines, to uncover a patient’s risk for clinically significant prostate cancer. Learn how the Select mdx urine test can reveal your risk. https://ow.ly/usXq50QI3tq

🎗 #PinkOctober 𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄 the average risk of developing breast cancer by age 70 years is 𝟲𝟱% for BRCA1 mutation carriers? #Philips brings together people, processes, and best-in-class imaging technologies to help providers and patients navigate the care journey with confidence. 🔎Discover how at https://lnkd.in/dGWzp_3A #MR #MRI #cancercare #breastcancerawareness